File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical Characteristics, Genetic Basis and Healthcare Resource Utilisation and Costs in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia: A Retrospective Cohort Study

TitleClinical Characteristics, Genetic Basis and Healthcare Resource Utilisation and Costs in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia: A Retrospective Cohort Study
Authors
KeywordsCPVT
genetics
HCRU
tachycardia
Issue Date2022
Citation
Reviews in Cardiovascular Medicine, 2022, v. 23, n. 8, article no. 276 How to Cite?
AbstractBackground: This study examined the clinical characteristics, genetic basis, healthcare utilisation and costs of catecholaminergic ventricular tachycardia (CPVT) patients from a Chinese city. Methods: This was a territory-wide retrospective cohort study of consecutive CPVT patients at public hospitals or clinics in Hong Kong. Healthcare resource utilisation for accident and emergency (A&E), inpatient and outpatient attendances were analysed over 19 years (2001–2019) followed by calculations of annualised costs (in USD). Results: Sixteen patients with a median presentation age (interquartile range (IQR) of 11 (9–14) years old) were included. Fifteen patients (93.8%) were initially symptomatic. Ten patients had both premature ventricular complexes (PVCs) and ventricular tachycardia/fibrillation (VT/VF). One patient had PVCs without VT/VF. Genetic tests were performed on 14 patients (87.5%). Eight (57.1%) tested positive for the ryanodine receptor 2 (RyR2) gene. Seven variants have been described elsewhere (c.14848G>A, c.12475C>A, c.7420A>G, c.11836G>A, c.14159T>C, c.10046C>T and c.7202G>A). c.14861C>G is a novel RyR2 variant not been reported outside this cohort. Patients were treated with beta-blockers (n = 16), amiodarone (n = 3) and verapamil (n = 2). Sympathectomy (n = 8) and implantable-cardioverter defibrillator implantation (n = 3) were performed. Over a median follow-up of 13.3 years (IQR: 8.4–18.1) years, six patients exhibited incident VT/VF. At the patient level, the median (IQR) annualised costs for A&E, inpatient and outpatient attendances were $66 (40–95), $10521 (5240–66887) and $791 (546–1105), respectively. Conclusions: All patients presented before the age of 19. The yield of genetic testing was 57%. The most expensive attendance type was inpatient stays, followed by outpatients and A&E attendances.
Persistent Identifierhttp://hdl.handle.net/10722/336871
ISSN
2023 Impact Factor: 1.9
2023 SCImago Journal Rankings: 0.518
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChung, Cheuk To-
dc.contributor.authorLee, Sharen-
dc.contributor.authorZhou, Jiandong-
dc.contributor.authorChou, Oscar Hou In-
dc.contributor.authorLee, Teddy Tai Loy-
dc.contributor.authorLeung, Keith Sai Kit-
dc.contributor.authorJeevaratnam, Kamalan-
dc.contributor.authorWong, Wing Tak-
dc.contributor.authorLiu, Tong-
dc.contributor.authorTse, Gary-
dc.date.accessioned2024-02-29T06:57:06Z-
dc.date.available2024-02-29T06:57:06Z-
dc.date.issued2022-
dc.identifier.citationReviews in Cardiovascular Medicine, 2022, v. 23, n. 8, article no. 276-
dc.identifier.issn1530-6550-
dc.identifier.urihttp://hdl.handle.net/10722/336871-
dc.description.abstractBackground: This study examined the clinical characteristics, genetic basis, healthcare utilisation and costs of catecholaminergic ventricular tachycardia (CPVT) patients from a Chinese city. Methods: This was a territory-wide retrospective cohort study of consecutive CPVT patients at public hospitals or clinics in Hong Kong. Healthcare resource utilisation for accident and emergency (A&E), inpatient and outpatient attendances were analysed over 19 years (2001–2019) followed by calculations of annualised costs (in USD). Results: Sixteen patients with a median presentation age (interquartile range (IQR) of 11 (9–14) years old) were included. Fifteen patients (93.8%) were initially symptomatic. Ten patients had both premature ventricular complexes (PVCs) and ventricular tachycardia/fibrillation (VT/VF). One patient had PVCs without VT/VF. Genetic tests were performed on 14 patients (87.5%). Eight (57.1%) tested positive for the ryanodine receptor 2 (RyR2) gene. Seven variants have been described elsewhere (c.14848G>A, c.12475C>A, c.7420A>G, c.11836G>A, c.14159T>C, c.10046C>T and c.7202G>A). c.14861C>G is a novel RyR2 variant not been reported outside this cohort. Patients were treated with beta-blockers (n = 16), amiodarone (n = 3) and verapamil (n = 2). Sympathectomy (n = 8) and implantable-cardioverter defibrillator implantation (n = 3) were performed. Over a median follow-up of 13.3 years (IQR: 8.4–18.1) years, six patients exhibited incident VT/VF. At the patient level, the median (IQR) annualised costs for A&E, inpatient and outpatient attendances were $66 (40–95), $10521 (5240–66887) and $791 (546–1105), respectively. Conclusions: All patients presented before the age of 19. The yield of genetic testing was 57%. The most expensive attendance type was inpatient stays, followed by outpatients and A&E attendances.-
dc.languageeng-
dc.relation.ispartofReviews in Cardiovascular Medicine-
dc.subjectCPVT-
dc.subjectgenetics-
dc.subjectHCRU-
dc.subjecttachycardia-
dc.titleClinical Characteristics, Genetic Basis and Healthcare Resource Utilisation and Costs in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia: A Retrospective Cohort Study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.31083/j.rcm2308276-
dc.identifier.scopuseid_2-s2.0-85135881732-
dc.identifier.volume23-
dc.identifier.issue8-
dc.identifier.spagearticle no. 276-
dc.identifier.epagearticle no. 276-
dc.identifier.eissn2153-8174-
dc.identifier.isiWOS:000882337300011-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats